proxyvotesnow.com

Home › Companies › Korro Bio, Inc. › 2025-2026

Korro Bio, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Korro Bio, Inc.’s Form 8-K, filed 2026-06-11 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 4Ballot items
  • 123Asset managers
  • 488Fund votes
  • 2026-06-10Meeting date

Proxy season: 2024-2025 2025-2026

Explore Korro Bio, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Korro Bio, Inc.

These tallies are Korro Bio, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-11 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Korro Bio, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Nessan Bermingham 7,468,003---- 1,576,6601,875,955 Majority: yes
Elect Director: Rachel Meyers 7,368,284---- 1,676,3791,875,955 Majority: yes
2) Korro's stockholders approved, in a non-binding, advisory vote, the compensation of Korro's named executive officers. 9,009,73927,9886,936 --1,875,955 Majority: yes
3) Korro's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. 10,917,6212,738259 --0 Majority: yes

Source: Korro Bio, Inc., Form 8-K, filed with the SEC on 2026-06-11 — read the filing on EDGAR.

How asset managers voted at the Korro Bio, Inc. 2025-2026 meeting

Each item below shows how the 123 asset managers that disclosed a Korro Bio, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Non-Binding advisory vote to approve the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 9,009,739AGAINST: 27,988

Korro Bio, Inc.’s own tally for this item (“2) Korro's stockholders approved, in a non-binding, advisory vote, the compensation of Korro's named executive officers.”): 9,009,739 for, 27,988 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,422,571 outstanding shares: 62% for, 0.2% against (63% of the company cast a for/against vote).

The 123 asset managers below cast 99.7% of the shares they voted on this item FOR (8,496,500 for, 17,470 against).

FOR 99.7%
FOR: 8,496,500 (99.8%)AGAINST: 17,470 (0.2%)ABSTAIN: 2,164 (0.0%)
Largest asset managers voting on “Non-Binding advisory vote to approve the compensation of our named executive officers;” at Korro Bio, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Lynx1 Capital Management LP1,538,2960 00For
NEA Management Company, LLC1,299,2300 00For
Atlas Venture Life Science Advisors, LLC1,137,1490 00For
Venrock Adviser, LLC1,009,5000 00For
DRIEHAUS CAPITAL MANAGEMENT LLC450,0450 00For
Siren, L.L.C.347,7180 00For
Vanguard345,8890 00For
Nantahala Capital Management, LLC299,0360 00For
Point72276,8310 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.228,4000 00For
BlackRock226,49118 00For
Fidelity196,0110 00For
AQR158,0010 00For
Affinity Asset Advisors, LLC156,2500 00For
GEODE CAPITAL MANAGEMENT, LLC150,0510 00For
BALYASNY ASSET MANAGEMENT L.P.134,8200 00For
State Street109,431270 00For
RBB FUND, INC.62,8550 00For
Cornerstone National Bank & Trust Co56,6740 00For
Two Sigma37,7170 00For
Northern Trust36,1210 00For
MARSHALL WACE, LLP30,8520 00For
MELLON INVESTMENTS Corp27,2550 00For
Charles Schwab26,7720 00For
T. Rowe Price20,0460 00For

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

2. Election of two Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Nessan Bermingham

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%
FOR: 7,468,003WITHHELD: 1,576,660

Korro Bio, Inc.’s own tally for this item (“Elect Director: Nessan Bermingham”): 7,468,003 for, 1,576,660 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,422,571 outstanding shares: 51.8% for, 11% withheld (63% of the company cast a for/withheld vote).

The 31 asset managers below cast 100% of the shares they voted on this item FOR (484,351 for, 0 against).

FOR 62%ABSTAIN 38%
FOR: 484,351 (61.8%)ABSTAIN: 298,986 (38.2%)
Largest asset managers voting on “Election of two Class I directors, nominated by our board of directors, each to serve for a three-year term ex” at Korro Bio, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard322,7250 30For
Fidelity126,2170 32,8660For
BlackRock00 155,1530Abstain
RBB FUND, INC.00 62,8550Abstain
Charles Schwab13,3780 00For
QUANTITATIVE MASTER SERIES LLC00 10,3410Abstain
TIAA00 8,2830Abstain
Dimensional00 7,7620Abstain
Equitable4,7600 2,0260For
T. Rowe Price00 5,8780Abstain
Lincoln Financial4,5000 00For
Northern Trust4,3910 00For
Goldman Sachs3,2900 00For
Global X3,2420 00For
AIG/SunAmerica00 3,0580Abstain
Bridge Builder Trust00 2,8300Abstain
Pacific Life00 2,4380Abstain
John Hancock00 1,9980Abstain
Nationwide2980 7040Abstain
DWS00 9660Abstain
ProShares00 8880Abstain
State Street6200 00For
Calvert00 5980Abstain
Venerable Variable Insurance Trust5490 00For
Principal00 2450Abstain

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

3. Election of two Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Rachel Meyers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%
FOR: 7,368,284WITHHELD: 1,676,379

Korro Bio, Inc.’s own tally for this item (“Elect Director: Rachel Meyers”): 7,368,284 for, 1,676,379 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,422,571 outstanding shares: 51.1% for, 12% withheld (63% of the company cast a for/withheld vote).

The 31 asset managers below cast 100% of the shares they voted on this item FOR (516,773 for, 0 against).

FOR 66%ABSTAIN 34%
FOR: 516,773 (66.0%)ABSTAIN: 266,564 (34.0%)
Largest asset managers voting on “Election of two Class I directors, nominated by our board of directors, each to serve for a three-year term ex” at Korro Bio, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard322,7250 30For
Fidelity159,0830 00For
BlackRock00 155,1530Abstain
RBB FUND, INC.00 62,8550Abstain
Charles Schwab13,3780 00For
QUANTITATIVE MASTER SERIES LLC00 10,3410Abstain
TIAA8,2830 00For
Dimensional00 7,7620Abstain
Equitable00 6,7860Abstain
T. Rowe Price5,8780 00For
Lincoln Financial00 4,5000Abstain
Northern Trust00 4,3910Abstain
Goldman Sachs3,2900 00For
Global X3,2420 00For
AIG/SunAmerica00 3,0580Abstain
Bridge Builder Trust00 2,8300Abstain
Pacific Life00 2,4380Abstain
John Hancock00 1,9980Abstain
Nationwide2980 7040Abstain
DWS00 9660Abstain
ProShares00 8880Abstain
State Street00 6200Abstain
Calvert00 5980Abstain
Venerable Variable Insurance Trust5490 00For
Principal00 2450Abstain

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

4. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 10,917,621AGAINST: 2,738

Korro Bio, Inc.’s own tally for this item (“3) Korro's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 10,917,621 for, 2,738 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 14,422,571 outstanding shares: 76% for, 0.1% against (76% of the company cast a for/against vote).

The 31 asset managers below cast 100% of the shares they voted on this item FOR (783,337 for, 0 against).

FOR 100%
FOR: 783,337 (100.0%)
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at Korro Bio, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard322,7280 00For
Fidelity159,0830 00For
BlackRock155,1530 00For
RBB FUND, INC.62,8550 00For
Charles Schwab13,3780 00For
QUANTITATIVE MASTER SERIES LLC10,3410 00For
TIAA8,2830 00For
Dimensional7,7620 00For
Equitable6,7860 00For
T. Rowe Price5,8780 00For
Lincoln Financial4,5000 00For
Northern Trust4,3910 00For
Goldman Sachs3,2900 00For
Global X3,2420 00For
AIG/SunAmerica3,0580 00For
Bridge Builder Trust2,8300 00For
Pacific Life2,4380 00For
John Hancock1,9980 00For
Nationwide1,0020 00For
DWS9660 00For
ProShares8880 00For
State Street6200 00For
Calvert5980 00For
Venerable Variable Insurance Trust5490 00For
Principal2450 00For

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

Largest Korro Bio, Inc. shareholders voting in 2025-2026

Ranked by the number of Korro Bio, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 14,422,571 shares outstanding at the time of that meeting.

Top Korro Bio, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Lynx1 Capital Management LP 10.67%
2NEA Management Company, LLC 9.01%
3Atlas Venture Life Science Advisors, LLC 7.88%
4Venrock Adviser, LLC 7.00%
5DRIEHAUS CAPITAL MANAGEMENT LLC 3.12%
6Siren, L.L.C. 2.41%
7Vanguard 2.40%
8Nantahala Capital Management, LLC 2.07%
9Point72 1.92%
10ADAGE CAPITAL PARTNERS GP, L.L.C. 1.58%

Reported Korro Bio, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Korro Bio, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Lynx1 Capital Management LP 10.67% 13G
Venrock Healthcare Capital Partners III, L.P. 10.32% 13G
New Enterprise Associates 17, L.P. 9.95% 13D
BALYASNY ASSET MANAGEMENT L.P. 6.60% 13G
Steven A. Cohen 5.66% 13G
Atlas Venture Fund XI, L.P. 4.90% 13D
Vanguard Group 3.39% 13F
BlackRock 3.19% 13F
Point72 Biotech Private Investments, LLC 1.92% 13G
Citadel Advisors 1.87% 13F

Percentages above are of 14,422,571 shares outstanding, as reported by Korro Bio, Inc. on its Form 10-Q dated 2026-05-04 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Korro Bio, Inc.’s 10-Q dated 2026-05-04. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Korro Bio, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 123 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 488 separate fund positions. On the most widely held item on that ballot — Non-Binding advisory vote to approve the compensation of our named executive officers; — FOR was 99.6% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Korro Bio, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-11.

Korro Bio, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).